- call +1-201-465-4211
- email sales@mrinsights.biz
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
Scope of the Report:
This report studies the Patient Derived Xenograft/PDX Models market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Patient Derived Xenograft/PDX Models market by product type and applications/end industries.
Several types of immunodeficient mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, NOD-SCID mice, and recombination-activating gene 2 (Rag2)-knockout mice. The mice used must be immunocompromised to prevent transplant rejection. The NOD-SCID mouse is considered more immunodeficient than the nude mouse, and therefore is more commonly used for PDX models because the NOD-SCID mouse does not produce natural killer cells.
The global Patient Derived Xenograft/PDX Models market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Patient Derived Xenograft/PDX Models.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Mice Models
Rat Models
Market Segment by Applications, can be divided into
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Patient Derived Xenograft/PDX Models Market Overview
1.1 Product Overview and Scope of Patient Derived Xenograft/PDX Models
1.2 Classification of Patient Derived Xenograft/PDX Models by Types
1.2.1 Global Patient Derived Xenograft/PDX Models Revenue Comparison by Types (2017-2023)
1.2.2 Global Patient Derived Xenograft/PDX Models Revenue Market Share by Types in 2017
1.2.3 Mice Models
1.2.4 Rat Models
1.3 Global Patient Derived Xenograft/PDX Models Market by Application
1.3.1 Global Patient Derived Xenograft/PDX Models Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Pre-clinical Drug Development and Basic Cancer Research
1.3.3 Biomarker Analysis
1.4 Global Patient Derived Xenograft/PDX Models Market by Regions
1.4.1 Global Patient Derived Xenograft/PDX Models Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Patient Derived Xenograft/PDX Models Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Patient Derived Xenograft/PDX Models Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Patient Derived Xenograft/PDX Models Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Patient Derived Xenograft/PDX Models Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Patient Derived Xenograft/PDX Models Status and Prospect (2013-2023)
1.5 Global Market Size of Patient Derived Xenograft/PDX Models (2013-2023)
2 Manufacturers Profiles
2.1 Crown Bioscience
2.1.1 Business Overview
2.1.2 Patient Derived Xenograft/PDX Models Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Crown Bioscience Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.2 The Jackson Laboratory
2.2.1 Business Overview
2.2.2 Patient Derived Xenograft/PDX Models Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 The Jackson Laboratory Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.3 Champions Oncology
2.3.1 Business Overview
2.3.2 Patient Derived Xenograft/PDX Models Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Champions Oncology Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.4 Charles River Laboratories
2.4.1 Business Overview
2.4.2 Patient Derived Xenograft/PDX Models Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Charles River Laboratories Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.5 WuXi Apptec
2.5.1 Business Overview
2.5.2 Patient Derived Xenograft/PDX Models Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 WuXi Apptec Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.6 Oncodesign
2.6.1 Business Overview
2.6.2 Patient Derived Xenograft/PDX Models Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Oncodesign Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.7 Horizon Discovery
2.7.1 Business Overview
2.7.2 Patient Derived Xenograft/PDX Models Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Horizon Discovery Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.8 Pharmatest Services
2.8.1 Business Overview
2.8.2 Patient Derived Xenograft/PDX Models Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Pharmatest Services Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.9 Hera Biolabs
2.9.1 Business Overview
2.9.2 Patient Derived Xenograft/PDX Models Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Hera Biolabs Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.10 EPO Berlin-Buch
2.10.1 Business Overview
2.10.2 Patient Derived Xenograft/PDX Models Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 EPO Berlin-Buch Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.11 Xentech
2.11.1 Business Overview
2.11.2 Patient Derived Xenograft/PDX Models Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Xentech Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
2.12 Urolead
2.12.1 Business Overview
2.12.2 Patient Derived Xenograft/PDX Models Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Urolead Patient Derived Xenograft/PDX Models Revenue, Gross Margin and Market Share (2016-2017)
3 Global Patient Derived Xenograft/PDX Models Market Competition, by Players
3.1 Global Patient Derived Xenograft/PDX Models Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Patient Derived Xenograft/PDX Models Players Market Share
3.2.2 Top 10 Patient Derived Xenograft/PDX Models Players Market Share
3.3 Market Competition Trend
4 Global Patient Derived Xenograft/PDX Models Market Size by Regions
4.1 Global Patient Derived Xenograft/PDX Models Revenue and Market Share by Regions
4.2 North America Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
4.3 Europe Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
4.5 South America Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
5 North America Patient Derived Xenograft/PDX Models Revenue by Countries
5.1 North America Patient Derived Xenograft/PDX Models Revenue by Countries (2013-2018)
5.2 USA Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
5.3 Canada Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
5.4 Mexico Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
6 Europe Patient Derived Xenograft/PDX Models Revenue by Countries
6.1 Europe Patient Derived Xenograft/PDX Models Revenue by Countries (2013-2018)
6.2 Germany Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
6.3 UK Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
6.4 France Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
6.5 Russia Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
6.6 Italy Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Patient Derived Xenograft/PDX Models Revenue by Countries
7.1 Asia-Pacific Patient Derived Xenograft/PDX Models Revenue by Countries (2013-2018)
7.2 China Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
7.3 Japan Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
7.4 Korea Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
7.5 India Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
8 South America Patient Derived Xenograft/PDX Models Revenue by Countries
8.1 South America Patient Derived Xenograft/PDX Models Revenue by Countries (2013-2018)
8.2 Brazil Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
8.3 Argentina Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
8.4 Colombia Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Patient Derived Xenograft/PDX Models by Countries
9.1 Middle East and Africa Patient Derived Xenograft/PDX Models Revenue by Countries (2013-2018)
9.2 Saudi Arabia Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
9.3 UAE Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
9.4 Egypt Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
9.5 Nigeria Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
9.6 South Africa Patient Derived Xenograft/PDX Models Revenue and Growth Rate (2013-2018)
10 Global Patient Derived Xenograft/PDX Models Market Segment by Type
10.1 Global Patient Derived Xenograft/PDX Models Revenue and Market Share by Type (2013-2018)
10.2 Global Patient Derived Xenograft/PDX Models Market Forecast by Type (2018-2023)
10.3 Mice Models Revenue Growth Rate (2013-2023)
10.4 Rat Models Revenue Growth Rate (2013-2023)
11 Global Patient Derived Xenograft/PDX Models Market Segment by Application
11.1 Global Patient Derived Xenograft/PDX Models Revenue Market Share by Application (2013-2018)
11.2 Patient Derived Xenograft/PDX Models Market Forecast by Application (2018-2023)
11.3 Pre-clinical Drug Development and Basic Cancer Research Revenue Growth (2013-2018)
11.4 Biomarker Analysis Revenue Growth (2013-2018)
12 Global Patient Derived Xenograft/PDX Models Market Size Forecast (2018-2023)
12.1 Global Patient Derived Xenograft/PDX Models Market Size Forecast (2018-2023)
12.2 Global Patient Derived Xenograft/PDX Models Market Forecast by Regions (2018-2023)
12.3 North America Patient Derived Xenograft/PDX Models Revenue Market Forecast (2018-2023)
12.4 Europe Patient Derived Xenograft/PDX Models Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Patient Derived Xenograft/PDX Models Revenue Market Forecast (2018-2023)
12.6 South America Patient Derived Xenograft/PDX Models Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Patient Derived Xenograft/PDX Models Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Patient Derived Xenograft/PDX Models Picture
Table Product Specifications of Patient Derived Xenograft/PDX Models
Table Global Patient Derived Xenograft/PDX Models a
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
